Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results
المؤلفون المشاركون
Ramella, Sara
Alberti, Antonio Maria
Cammilluzzi, Eugenio
Fiore, Michele
Ippolito, Edy
Greco, Carlo
De Quarto, Angelo Luca
Ramponi, Sara
Apolone, Giovanni
Trodella, Lucio
Cesario, Alfredo
D’Angelillo, Rolando Maria
المصدر
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-08-04
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Aims.
To establish feasibility of the combination of Erlotinib and concurrent chemoradiation in pre-treated patients with locally advanced or metastatic NSCLC.
Materials and Methods.
Data regarding 60 consecutive patients with NSCLC previously treated with chemotherapy alone were prospectically collected.
All patients started Erlotinib concurrently with chemotherapy and radiation delivered to primary tumor.
These data were retrospectively analyzed (observational study).
Feasibility and toxicity were the primary endpoints, with response rate and progression being the secondary ones, while survival data are reported just as exploratory analysis.
The EGFR mutational status was recorded in 32% of cases and it was always wild type.
Results.
Compliance to the combination protocol was good.
Grade 3-4 esophagitis and acute lung toxicity occurred in 2% and 8% of patients, respectively.
No progressive disease was recorded in the majority of cases (65%).
Median OS and PFS were 23.3 and 4.7 months, respectively.
Patients not responding to chemotherapy administered prior to chemoradiation achieved an objective response rate of 53.3% and complete response in 13.3% of cases.
Conclusions.
The addition of Erlotinib to chemoradiation in inoperable NSCLCs is feasible with interesting efficacy profile.
These preliminary results warrant further investigation in patients with locally advanced nonmetastatic NSCLC with EGFR mutations.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Ramella, Sara& Alberti, Antonio Maria& Cammilluzzi, Eugenio& Fiore, Michele& Ippolito, Edy& Greco, Carlo…[et al.]. 2013. Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results. BioMed Research International،Vol. 2013, no. 2013, pp.1-5.
https://search.emarefa.net/detail/BIM-1004225
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Ramella, Sara…[et al.]. Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results. BioMed Research International No. 2013 (2013), pp.1-5.
https://search.emarefa.net/detail/BIM-1004225
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Ramella, Sara& Alberti, Antonio Maria& Cammilluzzi, Eugenio& Fiore, Michele& Ippolito, Edy& Greco, Carlo…[et al.]. Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results. BioMed Research International. 2013. Vol. 2013, no. 2013, pp.1-5.
https://search.emarefa.net/detail/BIM-1004225
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1004225
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر